drugset / Trial / NCT05303844
Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.
Timeline
- Start
- 2022-04-02
- Primary completion
- 2025-03-20
- Completion
- 2025-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | H101 | Other / unclassified | — | Other |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |